Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA)

This publication has 36 references indexed in Scilit:

• POSA11 Ceftolozane-Tazobactam for the Treatment of Complicated Infections in Hospital Settings - Results from a French Real-World Study
  Value in Health, 2022
• Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
  Infectious Diseases and Therapy, 2021
• Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States
  Diagnostic Microbiology and Infectious Disease, 2021
• Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States
  Annals of Emergency Medicine, 2021
• Factors influencing mortality in hospital-acquired pneumonia caused by Gram-negative bacteria in China
  Journal of Infection and Public Health, 2019
• Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
  International Journal of Antimicrobial Agents, 2019
• The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
  JAMA, 2016
• Nosocomial Gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes
  International Journal of Infectious Diseases, 2015
• Hospital-Acquired Infections
  Surgical Clinics of North America, 2012
• Increases in Mortality, Length of Stay, and Cost Associated With Hospital-Acquired Infections in Trauma Patients
  Archives of Surgery, 2011